Bocidelpar sulfate is a small molecule commercialized by Astellas Pharma, with a leading Phase III program in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis). According to Globaldata, it is involved in 6 clinical trials, of which 4 were completed, 1 is ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Bocidelpar sulfate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Bocidelpar sulfate is expected to reach an annual total of $53 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Bocidelpar sulfate Overview
MA-0211 is under development for the treatment of Duchenne muscular dystrophy (DMD), mitochondrial myopathies and chronic fatigue syndrome. It is administered through oral route. The drug candidate acts by targeting peroxisome proliferator-activated receptor delta (PPARdelta). It was also under development for Leber’s hereditary optic neuropathy (LHON), fatty acid oxidation disorders including Melas syndrome, Kearns-Sayre syndrome
Astellas Pharma Overview
Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, cancer, nephrology, infectious diseases, and metabolic diseases, immunodeficiency, and transplantation. The company strives to develop new drugs to address high unmet medical needs with focus on biology and modality. Its pipeline consists of drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Chuo-Ku, Tokyo, Japan.
The company reported revenues of (Yen) JPY1,518,619 million for the fiscal year ended March 2023 (FY2023), an increase of 17.2% over FY2022. In FY2023, the company’s operating margin was 8.4%, compared to an operating margin of 12.4% in FY2022. In FY2023, the company recorded a net margin of 6.5%, compared to a net margin of 9.6% in FY2022.
The company reported revenues of JPY392,147 million for the second quarter ended September 2023, an increase of 4.6% over the previous quarter.
For a complete picture of Bocidelpar sulfate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.